

RD General Agenda Topics – March 1, 2021

Briefings for Michal

- PRIA/registration overview 2/23rd (complete)
- Dicamba 2/18th (complete)
- Sulfoxaflor 3/4th (pre-meeting with Ed 3/1st)

New Active Ingredients (include original PRIA date)

- Tetraniliprole – PD signed. PRIA date **3/31/21** (Original PRIA date 3/27/19) (IVB3). FRN is signed. Significant comments on the PD (over 7000) including significant issues raised by pollinator stewardship council.
- Broflanilide – completed!
- Fluindapyr – PD signed. PRIA Date **3/5/21** (Original PRIA date 5/29/20) (FB)
- Trifludimoxazin – PD signed. PRIA date **4/21/21** (Original PRIA date 10/16/2020) (FHB)
- Picarbutrazox – PD signed. PRIA date **3/15/21** (Original PRIA date 10/16/2020) (FHB)
 - Package (FRN, FD, RTC, one pager) cleared OPP-IO; **waiting for FRN to post**
- Fluxametamide (import tolerance only, residue pilot) – signed **PRIA date 3/2/21** (Original PRIA due 2/1) – completed!
- L-Glufosinate Ammonium – Risk Assessment phase. PRIA date 10/12/2021. **ESA issue. Any feedback?**

Other Chemical Actions

- Dicamba (Dan K)
 - **Fexapan (Corteva) – 100% repack; approved**
 - **24 (c)s** –
 - GA has resubmitted – no cutoff date, reduced buffer distances
 - TN and NC submissions – both asking for soybean cutoff date of 7/30th (to match cotton)

Ex. 5 Deliberative Process (DP)

- Antibiotics – will need to brief the new team (Cynthia)
 - Oxytet – cherry; public process (perhaps not needed)
 - Consultation with partners – Kasugamyacin (almond, peach, apricot)
- Cyclaniliprole/flonicamid – first residential use; public process; teams are addressing RD IO

Ex. 5 Deliberative Process (DP)

- Seresto – pet collar with high rate of incidents (death and neuro); planning a briefing

Other Actions - AA-Level/OD/High Visibility Items

- FDA/EPA jurisdiction – follow up briefing for Ed 3/10th – **anything needed in particular?**
- COVID-19 Activities – Sect 18s –

- SW2 – other use sites being evaluated
- Grignard – other states
- Kraton – bi-weekly meetings
- Ionopure Air
- Acteev Facemasks
- OIG Audits
 - Dicamba – RD staff (Dan R and Dan K) interviewed; draft findings – comments delivered to OIG; sent follow up SOPs
 - New chemical registrations –final report issued – 2 corrective actions
 - 24C audit –final report issued – 5 corrective actions
 - PRIA payment procedures – existing corrective action - RD assuming the lead now that ISB is on board.
 - Conditional registration – work towards close out this year
- Final Efficacy Test Guidelines (Fire Ants, Pests of Pets): done; re-announce availability

Ex. 5 Deliberative Process (DP)

- AAPCO Label Project – VA, IN, ME etc. plus EPA
- FLS/FLAG: scheduling Coffee and Conversations for early this year on preparing for “trust” discussions with staff, roll-out of Performance Mgt toolkit. Will circulate A Guide for Teams via email and schedule follow-ups as desired.

Business/process/technology

- ISB – FEP/21-day backlog:
 - **backlog addressed by end of April; RD SWAT team addressing newer receipts**
 - **Michal feedback on expediting all covid actions?**
- eCSF/OPPEL – OPP priority?

Speaking Engagements –

- Gold Seal Updates for CLA/RISE Workgroup (Catherine Aubee, Shanta Adee, Marion Johnson, ITRMD participant), (date TBD) <<will follow up to see if this is still needed
- AMCA meeting (Virna Stillwaugh)

Ex. 5 Deliberative Process (DP)